Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Registry facts

Study at a glance

Phase

PHASE4

Enrollment

50 (ESTIMATED)

Start date

2025-07-10

Sponsor

Massachusetts Institute of Technology

Design

RANDOMIZED · PARALLEL · OTHER

Locations

1

Results record

Not present in registry snapshot

Using a randomized, double-blind, placebo-controlled, parallel-group study design, this scientific investigation will examine the effect of 3 milliliters (mL) of Epidiolex (100mg cannabidiol/mL) on behavioral, physiological, and neuroimaging measures of anxiety in subjects diagnosed with SAD. The study will enroll 50 subjects with SAD who will be randomized in a double-blind manner to receive either Epidiolex or placebo before experiencing the Trier Social Stress Test (TSST), the gold-standard for ethically inducing stress in a controlled laboratory setting. Following the TSST, neuroimaging measures of emotional processing and self-referential processing will be acquired using functional magnetic resonance imaging (fMRI). This study will be conducted primarily at Massachusetts Institute of Technology with research and clinical support from Massachusetts General Hospital.